ClinicalTrials.gg
Enrolling by invitationNCT07832396IMPLEMENTUpdated Nov 17, 2026

Community Study to Increase Mammogram Screening Among Overdue Women

An interventional study of Evidence-based behavioural intervention in Mammography, Mammography Screening and Screening Uptake, sponsored by National University Hospital, Singapore. Enrolling by invitation at 1 site in Singapore. Open to female participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Health services research

How we know

Updated Nov 17, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Non-randomized
Ages
50 Years to 69 Years
Sex
Female
01

Study summary

Breast cancer is the most common cancer among women in Singapore, and regular mammogram screening can detect breast cancer early when treatment is more effective. However, many eligible women do not attend regular mammogram screening despite national screening programs and free screening for eligible women enrolled in Healthier SG.

The IMPLEMENT Study is a community-based implementation study that will evaluate whether practical, low-cost behavioural interventions can increase mammogram screening among women who are overdue for screening or have never been screened. The interventions have previously been shown to be effective in randomized controlled trials conducted by the study team.

The study will be conducted in the Health District @ Queenstown (HD@QT). Women living in Happy Village @ Mei Ling will receive one behavioural intervention that has been shown to be effective in a previous randomized trial, while eligible women living in the remainder of HD@QT will receive usual care with no study intervention. Different implementation trials will be conducted for different screening populations, including women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram.

The primary objective is to determine whether implementing these evidence-based interventions in a real-world community setting increases the proportion of women completing mammography within four months. Results from this study will help determine whether these interventions can be integrated into community health programs to improve breast cancer screening participation in Singapore.

02

Conditions studied

  • Mammography
  • Mammography Screening
  • Screening Uptake

Keywords

  • Mammography
  • Real-world
  • implementation
  • Screening uptake
03

In context

Lead sponsor

National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singaporean citizen
  • Age 50-69 years
  • Registered patients of NUHS
  • No history of breast cancer
  • Eligible for free mammograms (Signed up with Healthier SG with a primary care provider within the NUHS Primary Care Network)
  • In each individual trial in this proposed series of trials, the participants will either be:

Repeat screeners: Have undergone a mammogram at least once in the past, but not within the past 2 years Never screeners: Have never done mammogram in the past (no records in EPIC) Active screeners: Have undergone a mammogram within the past 20-24 months but have not scheduled their next screening in Health Appointment System (HAS)

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of breast cancer in EPIC
  • Pregnant woman
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Evidence-based behavioural intervention

    Eligible women residing in Happy Village @ Mei Ling will receive the evidence-based behavioural intervention specified for their screening population. The intervention will be implemented in the community to increase mammography completion within four months. In Trial A on defaulted repeats screeners the intervention will be Mailed Reminder (MR) with dedicated hotline scheduling. In Trial 2 on never-screeners the intervention will be MR with Prescheduled Appointment. Women may also visit the Happy Village @ Mei Ling outpost in person for assistance with booking their appointments.

    Behavioral: Evidence-based behavioural intervention

  • No intervention
    Comparator group

    Eligible women residing in the remainder of HD@QT will receive usual care without the study-delivered behavioural intervention. Mammography completion will be assessed using the same outcome definition and follow-up period.

Interventions

  • BehavioralEvidence-based behavioural intervention

    Evidence-based behavioural intervention delivered to eligible women in Happy Village @ Mei Ling to encourage mammography screening. The specific intervention, delivery method, frequency, and duration will be defined for each screening population based on the corresponding previous randomized trial. In Trial 1 the intervention will be mailed reminder (MR) with dedicated appointment scheduling hotline. In Trial 2, the intervention will be MR with prescheduled appointment.

06

What researchers measure

Primary outcomes

  1. Proportion of eligible women who complete mammography within four months of intervention delivery.

    This community-based implementation study will evaluate the effectiveness of evidence-based behavioural interventions to increase mammography screening in eligible women residing in the Health District @ Queenstown. Eligible women living in Happy Village @ Mei Ling will receive the intervention assigned to their screening population, while eligible women living in the remainder of the health district will receive usual care. The study will include implementation cohorts of women who have never undergone mammography, women who are overdue for repeat mammography, and women who are due for their next mammogram. The intervention will be delivered in parallel to usual care, and allocation will be non-randomized based on residential location. Mammography completion will be assessed within four months of intervention delivery.

    Time frame: 4 month

Secondary outcomes

  1. Time from mailed reminder to mammography completion

    Time from intervention mailer delivery to completion of mammography, measured in days.

    Time frame: From mailer delivery through 4 months.

  2. Time to appointment booking

    Time from intervention mailer delivery to the first mammography appointment booking, measured in days.

    Time frame: From mailer delivery through 4 months.

Other outcomes

  1. Factors associated with mammography completion

    Exploratory analysis of the association between age, ethnicity, housing type, prior mammography history, and time since last mammogram, and mammography completion.

    Time frame: Baseline participant characteristics; mammography completion assessed within 4 months

  2. Mammography appointment no-show rate

    Proportion of booked mammography appointments not attended, among participants with available appointment attendance data.

    Time frame: From first appointment booking through 4 months after mailer delivery.

  3. Number of participants attending Happy Village outposts

    Number of participants in the implementation group who attend Happy Village outposts for screening-related support or services.

    Time frame: From intervention delivery through 4 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Apr 2027, 4 months later.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2028 → Apr 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 22, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Apr 1, 2027was Nov 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 1, 2026→Nov 16, 2026
Nov 17, 2026
Primary completion
Nov 1, 2028→Apr 1, 2027
Nov 17, 2026
Enrollment
15000→1500
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Nov 1, 2026→Nov 16, 2026
    Primary completion Nov 1, 2028→Apr 1, 2027
    Enrollment 15000→1500
    + 4 other changes: index terms, verification date, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07832396
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion